This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AR806
Description: RDEA806 is a non-nucleoside reverse transcriptase inhibitor (NNRTI), with once-daily dosing (8-13 hour half-life). In vitro preclinical tests have shown RDEA806 to be a potent inhibitor of a wide range of HIV viral isolates, including isolates that are resistant to efavirenz and other currently available NNRTIs.
Per the company, a major metabolite of RDEA806, RDEA594, is responsible for its uric acid lowering effects. RDEA594 inhibits the urate transporter in the kidney, URAT1.
In December 2006, Ardea Biosciences signed a definitive asset purchase agreement with Valeant Pharmaceuticals International. Under this agreement, Ardea acquired substantially all of the assets, including intellectual property, preclinical data, product inventory, and research equipment, necessary for Ardea to pursue three distinct pharmaceutical research and development programs. The three programs are:
- 800 Series Program. The 800 Series Program is directed toward the discovery of NNRTIs for the potential treatment of HIV. The lead clinical candidate from the program is AR806.
- 900 Series Program. The 900 Series Program is also directed toward the discovery of NNRTIs for the potential treatment of HIV. The compounds in the 900 Series Program are from a chemical class that is distinct from the chemical class being investigated in the 800 Series Program.
- 100 Series Program. The 100 Series Program is directed toward the discovery of small-molecule kinase inhibitors...See full deal structure in Biomedtracker
Partners: Valeant Pharmaceuticals International, Inc.
Additional information available to subscribers only: